Abeona Therapeutics (ABEO) Is Up 17.9% After ZEVASKYN Wins Permanent J-Code and Narrows Net Loss – Has The Bull Case Changed?

• Abeona Therapeutics recently reported a third-quarter 2025 net loss of US$5.16 million, a significant improvement from US$30.27 million a year earlier, as its efforts to commercialize ZEVASKYN for RDEB patients advance alongside expanded treatment center access.
• A pivotal development includes the Centers for Medicare and Medicaid Services establishing a permanent J-code for ZEVASKYN, poised to support broader reimbursement and access from January 2026.
• With a 17.90% weekly and 18.47% daily share price climb, we'll explore how reimbursement enhancements underpin Abeona's investment narrative amid ZEVASKYN's commercial progress.

AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Abeona Therapeutics' Investment Narrative?

Owning shares in Abeona Therapeutics means buying into the potential of ZEVASKYN as a meaningful therapy for RDEB, while also recognizing that short-term momentum now hinges even more on commercial execution and reimbursement access. The recent CMS assignment of a permanent J-code for ZEVASKYN is a pivotal real-world milestone, as it sets the stage for broader payer coverage and easier hospital adoption once it becomes effective in early 2026. This news meaningfully strengthens the company’s near-term catalyst: translating early demand into actual treated patients and recognized revenue. That said, while the recent rally reflects optimism around access and regulatory progress, risks remain, particularly the slight delay in first patient starts, the presence of insider selling, and a complicated history of one-off items in financials. These factors could impact expectations for revenue growth and profitability into next year.
But even with commercial tailwinds, investor caution around insider selling deserves attention.

Abeona Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Four community contributors on Simply Wall St estimate Abeona’s fair value from just over US$10 up to US$102 per share. While views are divided, recent developments around ZEVASKYN’s reimbursement could drive future shifts in these opinions. Explore more insights on how sentiment and catalysts might influence Abeona’s path.

Explore 4 other fair value estimates on Abeona Therapeutics - why the stock might be a potential multi-bagger!

Build Your Own Abeona Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Abeona Therapeutics research is our analysis highlighting 4 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Abeona Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abeona Therapeutics' overall financial health at a glance.

No Opportunity In Abeona Therapeutics?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Find companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 37 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com